Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study.
Mathurin FumeryJérôme FilippiVered AbitbolAmélie BironDavid LaharieMelanie SerreroRomain AltweggYoram BouhnikLaurent Peyrin BirouletCyrielle GillettaXavier RoblinGuillaume Pineton de ChambrunLucine VuittonAnne BourrierStephane NanceyJean-Marc GornetStephane NahonGuillaume BouguenStephanie ViennotMaria NachuryAurélien AmiotPublished in: Alimentary pharmacology & therapeutics (2021)
After 52 weeks, over one-half of patients with refractory UC were still treated by ustekinumab and one-third were in steroid-free clinical remission.